AD/PD 2026 | The limitations of currently approved treatments for Parkinson’s disease
Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, discusses the limitations of the currently approved therapies for Parkinson’s disease. Prof. Stocchi highlights that, although treatments can control symptoms for many years, there is still a need for better treatments to address limitations. This interview took place at the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have good treatment for Parkinson’s disease, good drugs. I mean, that can definitely control symptoms of Parkinson’s. This symptom control can actually last quite long. We talk about more than 10, 15 years but eventually this current treatment fails to completely control the disease or other symptoms come out such as dyskinesia, such as motor fluctuations, which are related to treatment itself or just because the disease progresses and unfortunately, imbalance, for example, can come out, cognitive dysfunction, and other non-motor problems in PD...
We have good treatment for Parkinson’s disease, good drugs. I mean, that can definitely control symptoms of Parkinson’s. This symptom control can actually last quite long. We talk about more than 10, 15 years but eventually this current treatment fails to completely control the disease or other symptoms come out such as dyskinesia, such as motor fluctuations, which are related to treatment itself or just because the disease progresses and unfortunately, imbalance, for example, can come out, cognitive dysfunction, and other non-motor problems in PD. So, despite these drugs helping a lot, PD patients still have limitations and we need better treatment, even from the symptomatic point of view.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
